Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.87 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.87 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | NCF1 | P14598 | 1/20 | 0.60 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.59 |
| ▸ | HTR3B | O95264 | 1/20 | 0.59 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.59 |
| ▸ | HTR3A | P46098 | 1/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507540 | 1.00 | CHRNB2 (0.87) | CHRNB2CHRNA4ADRB2NCF1PLD1 | |
| SCHEMBL3538787 | 1.00 | CHRNB2 (0.87) | CHRNB2CHRNA4ADRB2NCF1PLD1 | |
| Hydrochloric Acid SCHEMBL9066315 | 0.98 | CHRNB2 (0.84) | CHRNB2CHRNA4ADRB2NCF1PLD1 | |
| SCHEMBL3061045 | 0.93 | CHRNB2 (1.00) | CHRNB2CHRNA4ADRB2NCF1PLD1 | |
| SCHEMBL6350076 | 0.92 | CHRNB2 (0.91) | CHRNB2CHRNA4ADRB2NCF1PLD1 | |
| SCHEMBL3065598 | 0.90 | CHRNB2 (0.94) | CHRNB2CHRNA4ALDH1A1CHRNA7CHRNB4 | |
| SCHEMBL5171064 | 0.89 | CHRNB2 (0.71) | CHRNB2CHRNA4ALDH1A1CHRNA7CHRNB4 | |
| SCHEMBL5655866 | 0.89 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3 | |
| SCHEMBL28210749 | 0.86 | CHRNB2 (0.67) | CHRNB2CHRNA4ADRB2NCF1PLD1 | |
| Fumaric Acid SCHEMBL27454231 | 0.86 | CHRNB2 (0.67) | CHRNB2CHRNA4ADRB2NCF1PLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 658 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114806414-B | Silicon polishing composition, preparation method and application thereof | 万华化学集团电子材料有限公司 | 2023-07-11 | — | — | CN | claimed |
| CN-114806414-A | Silicon polishing composition, preparation method and application thereof | 万华化学集团电子材料有限公司 | 2022-07-29 | — | — | CN | claimed |
| US-20170174710-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2017-06-22 | — | — | US | claimed |
| CN-106800554-A | A kind of crystal formation of Pa Boxini dihydrochlorides and preparation method thereof | 上海科胜药物研发有限公司 | 2017-06-06 | — | — | CN | claimed |
| US-20150203515-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | BIOGEN MA, INC. | 2015-07-23 | — | — | US | claimed |
| EP-2300469-A2 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-30 | — | — | EP | claimed |
| WO-2009140128-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-11-19 | — | — | WO | claimed |
| US-20040072823-A1 | Heteroaryl diazacycloalkanes, their preparation and use; | NEUROSEARCH A/S | 2004-04-15 | — | — | US | claimed |
| CN-1277604-A | Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors | NEUROSEARCH AS (DK) | 2000-12-20 | — | — | CN | claimed |
| CN-122036605-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2026-05-15 | — | — | CN | disclosed |
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| EP-4739684-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-0244115-A2 | Phenyl-piperazine anti-arrhythmia agents | Pfizer Limited (GB) | 1987-11-04 | — | — | EP | disclosed |
| CN-87102873-A | Phenylpiperazine anti-dysrhythmia agents and preparation method thereof | — | 1987-10-28 | — | — | CN | disclosed |
| EP-0233051-A2 | Antiarrhythmic Agents | Pfizer Limited (GB) | 1987-08-19 | — | — | EP | disclosed |
| CN-87100652-A | ANTI-DYSRHYTHMIA AGENTS | — | 1987-08-19 | — | — | CN | disclosed |
| US-4442103-A | ANTIDEPRESSANTS | MERCK & CO., INC. (US) | 1984-04-10 | — | — | US | disclosed |
| US-4191765-A | 1-Aryloxy-2-hydroxy-3-aminopropanes | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | CHRNB2 2711/4885CHRNA4 2951/4885ADRB2 1055/4885 |
| US-20170174710-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | CHRNB2 244/4885CHRNA4 287/4885ADRB2 202/4885 |
| US-20150203515-A1 | COMPOUNDS THAT ARE S1P MODULATING AGENTS AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | CHRNB2 150/4885CHRNA4 167/4885ADRB2 369/4885 |
| US-20040072823-A1 | Heteroaryl diazacycloalkanes, their preparation and use; | OGFR, CBR3, OGFRL1 | CHRNB2 700/4885CHRNA4 1019/4885ADRB2 184/4885 |
| US-20250388584-A1 | TPK AGONIST AND METHOD FOR TREATING NEURODEGENERATIVE DISEASES USING SAME | PDXK, SLC19A2, NADK | CHRNB2 29/4885CHRNA4 79/4885ADRB2 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.